Comparison of efficacy of labetalol and methyldopa in patients with pregnancy-induced hypertension

Subhedar, Vaidehi S.; Inamdar, Saunitra; Hariharan, C.; Subhedar, Siddharth

doi:10.5455/2320-1770.ijrcog20130205

Cited by 15 publications

(16 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The present study found the adverse effects to be less in the patients receiving labetalol, and the side effects were minor and did not necessitate stoppage of any drugs or change of medications 10,12 . No significant difference was seen in the two groups regarding gestational age at delivery, type of delivery (vaginal or caesarean section) and number of preterm babies.…”

Section: Graph 1: Comparison Of Sbp and Dbp In Group A (Labetalol) Anmentioning

confidence: 77%

“…11 In the present study no significant difference between the two groups was observed regarding requirement of dose escalation. Some researchers have reported such a difference, which was probably due to higher frequency of administration of labetalol 11,12 . In a study wherein pregnant women with both types of HT (mild as well as severe) was included, the mean doses of both the drugs to control BP were found to be higher 12 .…”

Section: Graph 1: Comparison Of Sbp and Dbp In Group A (Labetalol) Anmentioning

confidence: 99%

See 1 more Smart Citation

Untitled

2017

IJPSR

View full text Add to dashboard Cite

Aim: Labetalol is useful in severe hypertension (HT) in pregnancy; however, there was a need to define its role in mild HT in pregnancy. The present study was done to evaluate efficacy of labetalol in mild HT in pregnancy, compare it with that of methyldopa, and compare the tolerability of methyldopa and labetalol in patients. Methods: A prospective drug comparative study was conducted for one year in 60 mild hypertensive pregnant women, with gestational age of ≥20 weeks, receiving either labetalol or methyldopa. The primary endpoint was control of blood pressure (BP). The parameters recorded for comparison were time and dose to control BP, dose escalation, urine albumin level, adverse effects, and pregnancy outcomes. Results: Both the drugs produced significant reduction in BP in the patients (p<0.001). The patients in both groups showed significant reduction of urine albumin. Same number of patients in both groups required dose escalation. Time to control BP was less in the patients receiving methyldopa than those receiving labetalol; however, the patients receiving labetalol reported lower prevalence of adverse effects. Conclusion: Labetalol and methyldopa were found to be equally efficacious in controlling BP and had equal maternal and fetal outcomes. Methyldopa brought quicker control of BP; however, labetalol was better tolerated. This suggested that methyldopa has a better control over the blood pressure during late pregnancy, while labetalol was more efficacious in controlling it in early pregnancy. Further studies with larger sample size would be pertinent.

show abstract

Section: Graph 1: Comparison Of Sbp and Dbp In Group A (Labetalol) Anmentioning

confidence: 77%

Section: Graph 1: Comparison Of Sbp and Dbp In Group A (Labetalol) Anmentioning

confidence: 99%

Untitled

2017

IJPSR

View full text Add to dashboard Cite

show abstract

“…11 Subhedar et al, 2013, there was a more significant fall in MAP in labetalol group compared to methyldopa group and also time required to control BP was 36.97 hrs in labetalol group and time taken to control BP was 42.22hrs in methyldopa group. 12 Lamming et al, there was a highly significant fall in MAP in the group treated with labetalol (p<0.001) but no significant fall was noted in the group tested with methyldopa (p value>0.05). 13 Similar response rates have been found in few more studies like-lardoux's group 82%, Michael 92%.…”

Section: Discussionmentioning

confidence: 95%

Safety and efficacy of methyldopa and labetalol in controlling blood pressure in hypertensive disorders of pregnancy

Pentareddy

Shailendra

Prasuna

et al. 2017

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

Background: Hypertensive disorders represent the most common medical complication of pregnancy, with a reported incidence of 6-10% and accounts for 15% of maternal mortality. Effective management of pregnancy induced hypertension is vital to improve maternal and foetal outcomes. As data are scarce on comparison of labetolol and methyldopa this study was undertaken. The objective of present study is compare the efficacy and safety of Labetalol versus Methyldopa in the management of Mild to Moderate pregnancy induced hypertension. To evaluate effect of both drugs on maternal and foetal outcomes.Methods: A comparative observational study is designed. 30 patients who received methyldopa and 30 patients who received labetalol were included in the study. Methyldopa was started at a dose of 250-500 mg thrice daily while labetalol was started at a dose of 100-400 mg twice daily. Patients were followed up during antenatal, intrapartum and postpartum period for efficacy, safety, maternal, and perinatal outcomes.Results: Methyldopa and Labetalol reduced mean systolic and mean diastolic blood pressures significantly. safety profile of both drugs was similar. Spontaneous vaginal deliveries were observed more with labetolol significantly.Conclusions: Labetalol is equally efficacious as methyldopa and well tolerated in the treatment of new onset hypertension during pregnancy.

show abstract

“…Adverse effects profile was similar to study conducted by Subhedar V et al and ElQarmalawi et al (Table 3). 18,26 Our study reported the effectiveness of methyldopa and nifedipine among 95 patients with moderate gestational hypertension with a follow up of four weeks. Nifedipine having an additional tocolytic action showed significant reduction of systolic blood pressure at one month compared to methyldopa.…”

Section: Discussionmentioning

confidence: 99%

“…14 Marked fall of both systolic and diastolic pressure generally between 24 and 48 hours from the start of using methyldopa was noticed by S. F. Hans et al 17 Subhedar V et al showed that treatment of hypertension in pregnancy with methyldopa will reduce Mean Arterial Pressure. 18 Nifedipine a type 2 calcium channel blocker inhibits the inward flow of calcium across the L-type slow channels of cellular membranes and used as antihypertensive treatment in pregnancy since years, proved its efficacy in treatment of high blood pressure along with safety to mother and fetus. 19 Nifedipine has been shown to cause relaxation of the uterine smooth muscle and hence its use as a tocolytic agent.…”

mentioning

confidence: 99%